To the Editor We read with great interest the recent randomized clinical trial assessing the effect of bisoprolol in patients with chronic obstructive pulmonary disease (COPD) who are at high risk for exacerbation. The study found that bisoprolol did not reduce the number of self-reported COPD exacerbations requiring oral corticosteroids, antibiotics, or both. Although the study provides valuable insights, we would like to express some concerns about the findings.
